|
| 37906083 | Fine-Tuning Adjuvant Endocrine Therapy for Early-Stage Breast Cancer: An Expert Consensus on Open Issues for Future Research. | Clin Cancer Res | 2024 |
| 36761431 | Editorial: Trabectedin, lurbinectedin, and other marine-derived anticancer alkaloids on solid cancer: Mechanisms of action, clinical impact, and future perspectives. | Front Oncol | 2023 |
| 38016718 | Randomized, open-label, phase II, biomarker study of immune-mediated mechanism of action of neoadjuvant subcutaneous trastuzumab in patients with locally advanced, inflammatory, or early HER2-positive breast cancer-Immun-HER trial (GOIRC-01-2016). | J Immunother Cancer | 2023 |
| 37659765 | Working tables on Hormone Receptor positive (HR+), Human Epidermal growth factor Receptor 2 negative (HER2-) early stage breast cancer: Defining high risk of recurrence. | Crit Rev Oncol Hematol | 2023 |
| 37950941 | Association of tumor-infiltrating lymphocytes with recurrence score in hormone receptor-positive/HER2-negative breast cancer: Analysis of four prospective studies. | Eur J Cancer | 2023 |
| 37543499 | Risk-Based Therapeutic Strategies for HER2-Positive Early Breast Cancer: A Consensus Paper. | Clin Breast Cancer | 2023 |
| 37573652 | A cost-consequence analysis of adding pertuzumab to the neoadjuvant combination therapy in HER2-positive high-risk early breast cancer in Italy. | Breast | 2023 |
| 37928813 | News from the San Antonio Breast Cancer Symposium 2022. | Breast Care (Basel) | 2023 |
| 37535875 | Opportunities and Challenges of Synthetic Data Generation in Oncology. | JCO Clin Cancer Inform | 2023 |
| 37189701 | Clinical Review on the Management of Breast Cancer Visceral Crisis. | Biomedicines | 2023 |
| 36950554 | Multigene signatures for early breast cancer in clinical practice: A report of the Lombardy genomic assays for breast cancer working group. | Front Oncol | 2023 |
| 37417941 | A Prognostic Model Based on Residual Cancer Burden and Tumor-Infiltrating Lymphocytes on Residual Disease after Neoadjuvant Therapy in HER2+ Breast Cancer. | Clin Cancer Res | 2023 |
| 37444533 | Unlocking the Potential of Circulating miRNAs in the Breast Cancer Neoadjuvant Setting: A Systematic Review and Meta-Analysis. | Cancers (Basel) | 2023 |
| 37239385 | Hereditary Cancer Syndromes: A Comprehensive Review with a Visual Tool. | Genes (Basel) | 2023 |
| 37371707 | The Role of Female Reproductive Hormones in the Association between Migraine and Breast Cancer: An Unanswered Question. | Biomedicines | 2023 |
| 37437366 | Platinum-based chemotherapy and PARP inhibitors for patients with a germline BRCA pathogenic variant and advanced breast cancer (LATER-BC): retrospective multicentric analysis of post-progression treatments. | Eur J Cancer | 2023 |
| 37003098 | Serum thymidine kinase activity in patients with HR-positive/HER2-negative advanced breast cancer treated with ribociclib plus letrozole: Results from the prospective BioItaLEE trial. | Eur J Cancer | 2023 |
| 37400291 | Corrigendum to "Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review" [Cancer Treat. Rev. 114 (2023) 102511]. | Cancer Treat Rev | 2023 |
| 37069173 | Prognostic significance of HER2-low status in HR-positive/HER2-negative advanced breast cancer treated with CDK4/6 inhibitors. | NPJ Breast Cancer | 2023 |
| 37296893 | Hope and Hype around Immunotherapy in Triple-Negative Breast Cancer. | Cancers (Basel) | 2023 |
| 37471574 | Sentinel lymph node biopsy versus axillary lymph node dissection in breast cancer patients undergoing mastectomy with one to two metastatic sentinel lymph nodes: sub-analysis of the SINODAR-ONE multicentre randomized clinical trial and reopening of enrolment. | Br J Surg | 2023 |
| 37028000 | A phase II study of pembrolizumab plus carboplatin in BRCA-related metastatic breast cancer (PEMBRACA). | ESMO Open | 2023 |
| 36697419 | The central role of pathology labs in breast cancer precision oncology: a call for action. | NPJ Breast Cancer | 2023 |
| 36720089 | Pandemic Phase-Adjusted Analysis of COVID-19 Outcomes Reveals Reduced Intrinsic Vulnerability and Substantial Vaccine Protection From Severe Acute Respiratory Syndrome Coronavirus 2 in Patients With Breast Cancer. | J Clin Oncol | 2023 |
| 36638600 | Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review. | Cancer Treat Rev | 2023 |
| 36900200 | Potential Role of Circulating miRNAs for Breast Cancer Management in the Neoadjuvant Setting: A Road to Pave. | Cancers (Basel) | 2023 |
| 34689176 | Long-term survival in a fraction of patients with metastatic breast cancer who received consolidation therapy with high-dose chemotherapy and autologous stem cell transplant between 2000 and 2015: an EBMT registry-based study. | Bone Marrow Transplant | 2022 |
| 35576848 | Persistence of long-term COVID-19 sequelae in patients with cancer: An analysis from the OnCovid registry. | Eur J Cancer | 2022 |
| 35638300 | Heterogeneity of triple-negative breast cancer: understanding the Daedalian labyrinth and how it could reveal new drug targets. | Expert Opin Ther Targets | 2022 |
| 35565264 | Immunotherapy for HER2-Positive Breast Cancer: Clinical Evidence and Future Perspectives. | Cancers (Basel) | 2022 |
| 35454806 | Definition of High-Risk Early Hormone-Positive HER2-Negative Breast Cancer: A Consensus Review. | Cancers (Basel) | 2022 |
| 35417006 | COVID-19 Sequelae and the Host Proinflammatory Response: An Analysis From the OnCovid Registry. | J Natl Cancer Inst | 2022 |
| 36551722 | Loco-Regional Treatment of the Primary Tumor in De Novo Metastatic Breast Cancer Patients Undergoing Front-Line Chemotherapy. | Cancers (Basel) | 2022 |
| 36612144 | Controversies and Opportunities in the Clinical Daily Use of the 21-Gene Assay for Prognostication and Prediction of Chemotherapy Benefit in HR+/HER2- Early Breast Cancer. | Cancers (Basel) | 2022 |
| 35902384 | Real-World Effectiveness of Denosumab and Bisphosphonates on Risk of Vertebral Fractures in Women with Breast Cancer Undergoing Treatment with Aromatase Inhibitors. | Calcif Tissue Int | 2022 |
| 36379199 | PARP-inhibitors for BRCA1/2-related advanced HER2-negative breast cancer: A meta-analysis and GRADE recommendations by the Italian Association of Medical Oncology. | Breast | 2022 |
| 36387212 | Extended adjuvant endocrine treatment for premenopausal women: A Delphi approach to guide clinical practice. | Front Oncol | 2022 |
| 36160422 | From seaside to bedside: Current evidence and future perspectives in the treatment of breast cancer using marine compounds. | Front Pharmacol | 2022 |
| 36158652 | Controversial topics in metastatic HR+/HER2- breast cancer: Guiding treatment by a modified Delphi approach. | Front Oncol | 2022 |
| 36152144 | Safety and Efficacy of Ribociclib in Combination with Letrozole in Patients with HR+, HER2- Advanced Breast Cancer: Results from the Italian Subpopulation of Phase 3b CompLEEment-1 Study. | Target Oncol | 2022 |
| 34906479 | Risks of breast and ovarian cancer for women harboring pathogenic missense variants in BRCA1 and BRCA2 compared with those harboring protein truncating variants. | Genet Med | 2022 |
| 35080505 | A Remote Monitoring System to Optimize the Home Management of Oral Anticancer Therapies (ONCO-TreC): Prospective Training-Validation Trial. | J Med Internet Res | 2022 |
| 34817562 | Time-Dependent COVID-19 Mortality in Patients With Cancer: An Updated Analysis of the OnCovid Registry. | JAMA Oncol | 2022 |
| 33123991 | HGF/c-Met Signalling in the Tumor Microenvironment. | Adv Exp Med Biol | 2021 |
| 33573335 | Analysis of Italian <i>BRCA1/2</i> Pathogenic Variants Identifies a Private Spectrum in the Population from the Bergamo Province in Northern Italy. | Cancers (Basel) | 2021 |
| 33564777 | International Comparisons of Harmonized Laboratory Value Trajectories to Predict Severe COVID-19: Leveraging the 4CE Collaborative Across 342 Hospitals and 6 Countries: A Retrospective Cohort Study. | medRxiv | 2021 |
| 33753569 | Systemic pro-inflammatory response identifies patients with cancer with adverse outcomes from SARS-CoV-2 infection: the OnCovid Inflammatory Score. | J Immunother Cancer | 2021 |
| 34777582 | COVID-19 in breast cancer patients: a subanalysis of the OnCovid registry. | Ther Adv Med Oncol | 2021 |
| 34042623 | i2b2 to Optimize Patients Enrollment. | Stud Health Technol Inform | 2021 |
| 33932726 | Determinants of enhanced vulnerability to coronavirus disease 2019 in UK patients with cancer: a European study. | Eur J Cancer | 2021 |